PURPOSE: Nucleotide oligomerization domain-2 (NOD2) plays an important role in innate immunity to sense muramyl dipeptide (MDP), a component of bacterial cell walls. Notably, NOD2 is linked to eye inflammation because mutations in NOD2 cause a granulomatous type of uveitis called Blau syndrome. A mouse model of NOD2-dependent ocular inflammation was employed to test the role of a cytokine strongly implicated in granuloma formation, IFN-gamma, in order to gain insight into downstream functional consequences of NOD2 activation within the eye triggering uveitis. METHODS: Mice deficient in IFN-gamma, NOD2, or CD11b and their wild-type controls were treated with intravitreal injection of MDP in the presence or absence of IFN-gamma. IFN-gamma production in the eye was measured by ELISA. The intravascular inflammatory response within the iris was quantified by intravital microscopy. RESULTS: NOD2 activation resulted in the production of IFN-gamma within the eye. Deficiency in IFN-gamma diminished the development of MDP-induced uveitis, indicating its crucial role in downstream inflammatory events triggered by NOD2. Moreover, exogenous IFN-gamma markedly exacerbated MDP-induced ocular inflammation in a NOD2-dependent mechanism. The potential of IFN-gamma to enhance inflammation required the adhesion molecule CD11b because CD11b-deficient mice failed to show the synergistic effects of IFN-gamma and MDP cotreatment on adhering and infiltrating cells. CONCLUSIONS: IFN-gamma was identified as a downstream mediator of NOD2-driven inflammation and the capacity of IFN-gamma in vivo to enhance the inflammatory potential of NOD2 was demonstrated. Extrapolation of these findings in mice suggests that the dysregulation of IFN-gamma may occur in patients with Blau syndrome, thereby contributing to the granulomatous nature of the disease.
PURPOSE:Nucleotide oligomerization domain-2 (NOD2) plays an important role in innate immunity to sense muramyl dipeptide (MDP), a component of bacterial cell walls. Notably, NOD2 is linked to eye inflammation because mutations in NOD2 cause a granulomatous type of uveitis called Blau syndrome. A mouse model of NOD2-dependent ocular inflammation was employed to test the role of a cytokine strongly implicated in granuloma formation, IFN-gamma, in order to gain insight into downstream functional consequences of NOD2 activation within the eye triggering uveitis. METHODS:Mice deficient in IFN-gamma, NOD2, or CD11b and their wild-type controls were treated with intravitreal injection of MDP in the presence or absence of IFN-gamma. IFN-gamma production in the eye was measured by ELISA. The intravascular inflammatory response within the iris was quantified by intravital microscopy. RESULTS:NOD2 activation resulted in the production of IFN-gamma within the eye. Deficiency in IFN-gamma diminished the development of MDP-induced uveitis, indicating its crucial role in downstream inflammatory events triggered by NOD2. Moreover, exogenous IFN-gamma markedly exacerbated MDP-induced ocular inflammation in a NOD2-dependent mechanism. The potential of IFN-gamma to enhance inflammation required the adhesion molecule CD11b because CD11b-deficient mice failed to show the synergistic effects of IFN-gamma and MDP cotreatment on adhering and infiltrating cells. CONCLUSIONS:IFN-gamma was identified as a downstream mediator of NOD2-driven inflammation and the capacity of IFN-gamma in vivo to enhance the inflammatory potential of NOD2 was demonstrated. Extrapolation of these findings in mice suggests that the dysregulation of IFN-gamma may occur in patients with Blau syndrome, thereby contributing to the granulomatous nature of the disease.
Authors: Qilin Pan; John Mathison; Colleen Fearns; Vladimir V Kravchenko; Jean Da Silva Correia; Hal M Hoffman; Koichi S Kobayashi; John Bertin; Ethan P Grant; Anthony J Coyle; Fayyaz S Sutterwala; Yasunori Ogura; Richard A Flavell; Richard J Ulevitch Journal: J Leukoc Biol Date: 2007-04-02 Impact factor: 4.962
Authors: Carlos D Rosé; Carine H Wouters; Silvia Meiorin; Trudy M Doyle; Michael P Davey; James T Rosenbaum; Tammy M Martin Journal: Arthritis Rheum Date: 2006-10
Authors: Shao Bo Su; Rafael S Grajewski; Dror Luger; Rajeev K Agarwal; Phyllis B Silver; Jun Tang; Jingsheng Tuo; Chi-Chao Chan; Rachel R Caspi Journal: Invest Ophthalmol Vis Sci Date: 2007-10 Impact factor: 4.799
Authors: H L Rosenzweig; M M Jann; T T Glant; T M Martin; S R Planck; W van Eden; P J S van Kooten; R A Flavell; K S Kobayashi; J T Rosenbaum; M P Davey Journal: J Leukoc Biol Date: 2009-01-07 Impact factor: 4.962
Authors: Sabine Tötemeyer; Mark Sheppard; Adrian Lloyd; David Roper; Christopher Dowson; David Underhill; Peter Murray; Duncan Maskell; Clare Bryant Journal: J Immunol Date: 2006-04-15 Impact factor: 5.422
Authors: Holly L Rosenzweig; Kellen Galster; Emily E Vance; Joe Ensign-Lewis; Gabriel Nunez; Michael P Davey; James T Rosenbaum Journal: Invest Ophthalmol Vis Sci Date: 2011-06-09 Impact factor: 4.799